Among them, Nobiletin was reported to enhance chemosensitivity to adriamycin by modulating the Akt/GSK3β/β-Catenin/MYCN/MRP1 signalling pathway in A549 human non-small cell lung cancer cells (Moon et al. 2018). This evidence concerns the gene MYCN and non-small cell lung carcinoma.